Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 6/20 | 0.40 |
| ▸ | RBP4 | P02753 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24433939 | 0.92 | FAAH (0.39) | FAAHRBP4CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL23912861 | 0.92 | FAAH (0.39) | FAAHRBP4 | |
| SCHEMBL23912885 | 0.92 | FAAH (0.37) | FAAHRBP4SLC6A9CNR1 | |
| SCHEMBL24433947 | 0.90 | FAAH (0.35) | FAAHRBP4CNR1 | |
| SCHEMBL24433911 | 0.84 | FAAH (0.34) | FAAHRBP4SLC6A9CNR1 | |
| SCHEMBL23912872 | 0.84 | LMNA (0.43) | FAAHRBP4CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL4085241 | 0.83 | LMNA (0.48) | FAAHRBP4CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL4078438 | 0.82 | FAAH (0.47) | FAAHRBP4CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL24433940 | 0.77 | NAAA (0.38) | FAAH | |
| SCHEMBL4407420 | 0.77 | FAAH (0.42) | FAAHRBP4CYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11141404-B1 | Formulations and methods for treating acute cannabinoid overdose | ANEBULO PHARMACEUTICALS, INC. (US) | 2021-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11141404-B1 | Formulations and methods for treating acute cannabinoid overdose | CNR1, CNR2, FAAH | FAAH 3/4885RBP4 3417/4885CYP3A4 984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.